August 26, 2026: the U.S. FDA approved daraxonrasib (RASONQUE) for metastatic pancreatic adenocarcinoma, the first RAS-targeted therapy approved for pancreatic cancer. All news →
Daraxonrasib RMC-6236 · RASONQUE

References

Regulatory documents, peer-reviewed literature, trial registrations and official resources

Regulatory documents

  1. FDA approves daraxonrasib for metastatic pancreatic adenocarcinoma
    U.S. Food and Drug Administration. FDA drug approval notice, 2026
    https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-daraxonrasib-metastatic-pancreatic-adenocarcinoma

Publications

  1. Daraxonrasib versus chemotherapy in previously treated metastatic pancreatic cancer (RASolute 302)
    O'Reilly EM, Wolpin BM, et al.. New England Journal of Medicine, 2026
    https://www.nejm.org/
  2. Daraxonrasib in previously treated RAS-mutant non-small-cell lung cancer: phase 1/2 results
    Hong DS, et al.. New England Journal of Medicine, 2026
    https://www.nejm.org/

Trial registrations

  1. RASolute 302: Phase 3 study of daraxonrasib vs. standard of care chemotherapy in previously treated metastatic PDAC
    ClinicalTrials.gov. NCT06625320, 2024
    https://clinicaltrials.gov/study/NCT06625320
  2. RASolve 301: Study of daraxonrasib in patients with RAS mutated NSCLC
    ClinicalTrials.gov. NCT06881784, 2025
    https://clinicaltrials.gov/study/NCT06881784
  3. RMC-6236-001: First-in-human study of RMC-6236 in RAS-mutant solid tumors
    ClinicalTrials.gov. NCT05379985, 2022
    https://clinicaltrials.gov/study/NCT05379985

Official websites

  1. Revolution Medicines official website
    Revolution Medicines, Inc.. Corporate website
    https://www.revmed.com
  2. Revolution Medicines clinical trial finder
    Revolution Medicines, Inc.. Clinical trial information
    https://revmedclinicaltrials.com/

News

  1. Daraxonrasib Demonstrates Unprecedented Overall Survival Benefit in Pivotal Phase 3 RASolute 302 Clinical Trial
    Revolution Medicines. Company press release, 2026
    https://ir.revmed.com/news-releases/news-release-details/daraxonrasib-demonstrates-unprecedented-overall-survival-benefit
  2. Revolution Medicines Announces FDA Breakthrough Therapy Designation for Daraxonrasib
    Revolution Medicines. Company press release, 2025
    https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-announces-fda-breakthrough-therapy
  3. Daraxonrasib Nearly Doubles Survival in Previously Treated Metastatic Pancreatic Cancer
    The ASCO Post. ASCO 2026 congress coverage, 2026
    https://ascopost.com/issues/june-10-2026/daraxonrasib-nearly-doubles-survival-in-previously-treated-metastatic-pancreatic-cancer/
Content on this site is provided for informational purposes for healthcare professionals and the public. It does not constitute medical advice, diagnosis or treatment. Always follow your physician's guidance and the official prescribing information. Read the full disclaimer